Company Profiles

driven by the PitchBook Platform

Axon Neuroscience

Axon Neuroscience
1999 FOUNDED
PRIVATE STATUS
51-60 EMPLOYEES
Early Stage VC LATEST DEAL TYPE
$1.64M LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of disease modifying immunotherapeutics for the treatment of Alzheimer's disease. The company's disease modifying immunotherapeutics focus to enhance the quality of life for patients suffering from Alzheimer's disease and Frontotemporal lobar degeneration, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
  • Dvorákovo nábrežie 10
  • Slovak Republic
  • Bratislava, 811 02
  • Slovakia

+421 02/209 000 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Axon Neuroscience’s full profile, request a free trial.

Axon Neuroscience Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 01-Mar-2003 $1.64M 00.000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Axon Neuroscience Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Horizonte Venture Management Asset Manager Minority 000 0000 000000 0

Axon Neuroscience Executive Team (6)

Name Title Board
Seat
Contact
Info
Martin Cabadaj Co-Chief Executive Officer & Owner
Roman Sivak Co-Chief Executive Officer
Ladislav Satko Chief Financial Officer
Norbert Zilka Ph.D Chief Science Officer
Michal Novak Ph.D Co-Founder & Chairman of the Scientific Advisory Board

1 Former Executive

You’re viewing 5 of 6 executives. Get the full list »

Axon Neuroscience Board Members (1)

Name Representing Role Since Contact
Info
Michal Novak Ph.D Axon Neuroscience Co-Founder & Chairman of the Scientific Advisory Board 000 0000